Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity

10.1111/bcp.13008

Saved in:

Bibliographic Details
Main Authors:	Aminkeng, Folefac, Ross, Colin JD, Rassekh, Shahrad R, Hwang, Soomi, Rieder, Michael J, Bhavsar, Amit P, Smith, Anne, Sanatani, Shubhayan, Gelmon, Karen A, Bernstein, Daniel, Hayden, Michael R, Amstutz, Ursula, Carleton, Bruce C
Other Authors:	MEDICINE
Format:	Review
Language:	English
Published:	WILEY 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy anthracycline cardiotoxicity heart-failure guidelines pharmacogenomics cancer ACUTE LYMPHOBLASTIC-LEUKEMIA ADVANCED BREAST-CANCER CONTINUOUS INTRAVENOUS-INFUSION DOXORUBICIN-INDUCED CARDIOTOXICITY LIPOSOME-ENCAPSULATED DOXORUBICIN ADRIAMYCIN-INDUCED CARDIOMYOPATHY CONGESTIVE-HEART-FAILURE NON-HODGKIN-LYMPHOMA LONG-TERM SURVIVORS B-CELL LYMPHOMA
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/235077
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Description
Summary:	10.1111/bcp.13008